Packages (Simulation)
Quality Guarantee
Certificate
ELISA Kit DIY Materials for Fibrinogen Beta Chain (FGB)
FG-B; Fibrinopeptide B; Fibrinogen Beta
- Product No.KSB215Hu01
- Organism SpeciesHomo sapiens (Human) Same name, Different species.
- Reagent Contents Capture Antibody, Detection Antibody, Standard, Streptavidin-HRP, TMB Substrate, 96-well Plate
- Detectable SamplePlasma.
- Applicable PrincipleDouble-antibody Sandwich ELISA for Antigen Detection
- Detectable Range7.81-500ng/mL
- Applicable Sensitivity3.4ng/mL
- ApplicationsMain materials for "Do It (ELISA Kit) Yourself".
- Downloadn/a
- UOM 96T*596T*10 96T*20 96T*50 96T*100
- FOB
US$ 1197
US$ 1995
US$ 3591
US$ 6983
US$ 11970
For more details, please contact local distributors!
SPECIFITY
The Abs in the kit have high sensitivity and excellent specificity for detection of Fibrinogen Beta (FGb). No significant cross-reactivity or interference between Fibrinogen Beta (FGb) and analogues was observed.
USAGE
1. Coat the plates with 100μL per well of working solution of Capture Antibody.incubate overnight at 4°C or incubate at 37°C for 2 hours.
2. Aspirate and wash 1 time.
3. Block the plates with 200 μL per well of working solution of Blocking Buffer. Incubate at 37°C for 1.5 hours.
4. Aspirate and wash 1 time. The plates are now ready for sample detection, the protocol is the same as regular ELISA.
STORAGE
Antibodies, Standard and Streptavidin-HRP should be stored at -20°C. TMB should be stored at 4°C. 96-well Plate could be stored at room temperature. The contents are valid for twelve months. They are stable for one month after opening when stored at 4°C.
Support Pack
GIVEAWAYS
INCREMENT SERVICES
| Magazine | Citations |
| United States Patent Application | Compositions and Methods for Diagnosing Lung Cancer y2016:0077095.html |
| Microbial Pathogenesis | Crystal structure of GAPDH of Streptococcus agalactiae and characterization of its interaction with extracellular matrix molecules Pubmed: 30553015 |
| GLYCOCONJUGATE JOURNAL | Nattokinase-heparin exhibits beneficial efficacy and safety—an optimal strategy for CKD patients on hemodialysis Pubmed: 30788657 |